CAI — Caris Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00- $10.40bn
- $10.06bn
- $412.26m
- 45
- 11
- 66
- 35
Annual balance sheet for Caris Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 125 | 67.6 |
| Net Total Accounts Receivable | ||
| Net Total Receivables | 55.3 | 88.2 |
| Total Inventory | ||
| Prepaid Expenses | ||
| Total Other Current Assets | ||
| Total Current Assets | 243 | 216 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 107 | 67.8 |
| Net Goodwill | ||
| Other Long Term Assets | ||
| Total Assets | 413 | 344 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 95.1 | 165 |
| Long Term Debt | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Total Other Liabilities | ||
| Total Liabilities | 433 | 621 |
| Redeemable Preferred Stock | ||
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Treasury Stock | ||
| Other Equity | ||
| Total Equity | -19.7 | -277 |
| Total Liabilities & Shareholders' Equity | 413 | 344 |
| Total Common Shares Outstanding |